Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
ApexOnco Front Page
Recent articles
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
GEN1286/PRO1286 features among the latest industry projects to enter clinical trials.
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.
The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.
NXP800 yields neither severe thrombocytopenia, nor any responses.
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
